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Abstract. While being the most abused psychoactive substance (PS), cannabis is also
the least researched PS (especially) in Indonesia. Since 24% of total PS abusers within
the last year is students, we could only form an a priori on what cannabis consumption
might lead to for the cognitive functions of the students. A study to explore what would
happen to cognitive functions due to cannabis consumption is important. This article
aims (1) to explore the effects induced by cannabis in human cognitive functions and
(2) to explore which part of the brain correlates with cognitive functions affected by
cannabis consumption. We conducted a literature review to answer the questions. This
article shows that there is no clear conclusion whether cannabis induced positive or
negative effects to human cognitive functions. It is due to various sampling technique
used by the studies cited within this article. Future research on the cognitive functions
of cannabis consumer should really taking population in which they tried to sample
into consideration. Moreover, it is delicate to determine causality relationship between
consuming cannabis and poor cognitive functions.
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Introduction
Cannabis is a genus of flowering plant as well as PS. In 2017, an estimated 1,7 million people
in Indonesia aged 10-59 years consumed this flowering plant in the previous year, making it the
most consumed PS in Indonesia (Pusat Penelitian Data dan Informasi Badan Narkotika Nasional
Republik Indonesia [BNN] & Pusat Penelitian Kesehatan Universitas Indonesia [UI] (BNN & UI,
2017)). However, while listed as the most consumed, cannabis is the least researched PS in Indonesia1
(Saputro, 2018). This anomaly contradicts the fact that in Indonesia, cannabis could only be researched
and/or as diagnostic reagent and not to be consumed (Undang-undang Nomor 35 Tahun 2009 tentang
Narkotika, 2009).
Twenty-four percent of the previous year prevalence (3.3 million) were students (BNN & UI,
2017), which were approximately adolescence, a phase when the brain is experiencing fundamental
reorganization (Konrad et al., 2013). According to Konrad et al. (2013), this fundamental reorganization
*Address for correspondence: wurgan.rahadian@mail.ugm.ac.id
1BNN through a letter numbered B/2474/X/201/BNN to Lingkar Ganja Nusantara (LGN) on 6 October 2011
confirmed that there is no specific study formally conducted by Indonesian government towards cannabis
(Nusantara, 2014). However, Sujono and Daniel (2013) state that BNN with Indonesia National Institute on
Drug Abuse and Monash University ever conducted a study towards cannabis. Moreover, not only in Indonesia,
compared to other PS, cannabis is the least studied PS globally (Balhara & Jain, 2014).
204 BULETIN PSIKOLOGI
Rahadian et al ‖ Cognitive Deficiency
is associated with the extent of emotional and cognitive maturation. Cognitive maturation is shaped
by the development of executive function, which governs on how we think and behave, resulting in
flexible adaptability to a new and more complex tasks (Blakemore & Choudhury, 2006) In addition to
executive function, cognitive maturation is also shaped by the development of social cognitive, e.g.,
ability to recognize faces and to empathize (Blakemore, 2008).
It is important to study the effects cannabis might induce to cognitive functions, since a
longitudinal study shows that cannabis consumption during adolescence correlates with schizophrenia
onset in adulthood (Arseneault et al., 2002). In line with Arseneault et al. (2002), another longitudinal
study shows that there is a correlation between cannabis consumption during young adulthood and
symptoms associated with schizophrenia (Andréasson et al., 1987). Nevertheless, both longitudinal
studies did not consider predisposition factor before the onset of cannabis consumption.
Although there is a correlation between cannabis consumption and schizophrenia (Andréasson
et al., 1987; Arseneault et al., 2002)), it does not imply that cannabis consumption might induce
schizophrenia. Individuals with predisposition to schizophrenia tend to consume cannabis (Pinel,
2009). However, a background check to psychosis incidence during childhood should be made to
prevent future consumption to cannabis (Arseneault et al., 2002). Furthermore, in non-predisposition
group—even though the study did not divide between predisposition and non-predisposition groups;
general population—cannabis consumption accounts for only a minority of all schizophrenia cases
(Andréasson et al., 1987).
Recent studies show antipsychotic properties of one of the cannabinoids2 Cannabidiol (CBD)
as a constituent of the cannabinoids and mostly binds to cannabinoid receptor type 2 (CB2) might
induce antipsychotic effect (Emmet & Nice, 2009; Iseger & Bossong, 2015; Kloft, 2017; Peres et al., 2017;
Walkey et al., 2018). New evidence supported antipsychotic effect of CBD; lack of CB2 stimulation
might increase the risk of developing schizophrenia (Ishiguro et al., 2010). Moreover, antipsychotic
effect of CBD is as potent as amisulpride3 with more tolerated side effects (Leweke et al., 2012).
Not only show potential as treatment for schizophrenia, cannabis also shows potential as
a treatment for individual with neurodegenerative diseases (Bassavarajappa et al., 2017), e.g.,
Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease (HD), and
Parkinson’s disease (PsD) (Fernández-Ruiz et al., 2015; Singh & Joshi, 2019). Cannabis could induce
neuroprotection/neurorepair and anti-inflammatory properties through cannabinoid, thus impair the
disease progression and alleviating related symptoms (Fernández-Ruiz et al., 2017; Holgado et al.,
2017). The findings suggested CB2 agonist and cannabinoid receptor type 1 (CB1)4 antagonist to be
used as a treatment to neurodegenerative diseases (Bassavarajappa et al., 2017; Cassano et al., 2017).
2Cannabinoids are chemical compounds found in cannabis There are two main cannabinoids, i.e.,
delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) (Emmet & Nice, 2009). The two of them have
opposing effects, while Δ9-THC might induce psychotic-like effects, CBD might induce antipsychotic effects
(Iseger & Bossong, 2015; Walkey et al., 2018).
3A potent antipsychotic drug (Leweke et al., 2012).
4Along with CB1, endogenously produced cannabinoids (endocannabinoids) that binds to cannabinoid receptor,
and catabolic enzymes to cannabinoids, they formed the endocannabinoid system (ECS) (Bassavarajappa et al.,
2017).
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Based on presented preliminary data, this article aims (1) to explore the effects induced by
cannabis in human cognitive functions and (2) to explore which part of the brain correlated with
cognitive functions affected by cannabis consumption. Both objectives are important since cannabis
is the most consumed but the least researched PS (especially) in Indonesia. Moreover, it is important
since 24% of the previous year prevalence are student (BNN & UI, 2017)).
Cannabis and Cognitive Functions
Memorizing, reasoning, thinking, and perception are parts of cognitive functions (Evren, 2017). Poorer
cognitive function often associated with chronic and heavy consumption to cannabis (Sagar & Gruber,
2018). Moreover, cannabis consumption during adolescence often associated with poorer attention,
memory, processing, IQ, inhibition, and decision-making ability (Wright et al., 2017).
However, the associations could not be generalized. Many other studies suggested the opposite.
One of them came from Indonesia, as Widodo and Surjaningrum (2014) found that there is no
significant difference on working memory test5 between cannabis consumers and non-consumers6.
Population based studies shows that there is no significant difference on the cognitive functions
between cannabis consumers and non-consumers (Ross et al., 2020; Scott et al., 2017). Furthermore,
occasional consumers (≤2 per week; n=940) tend to perform slightly better than non-consumers
on executive control, social cognition, and memory test (Scott et al., 2017). Besides, through
quasi-experiment design on twins (n=856) from 438 families, it could be summarized that moderate
consumption to cannabis did not lead to poorer cognitive functions (Ross et al., 2020). Population
based research in Germany also suggested that consuming cannabis on mild to moderate level did not
lead to poorer executive functions (Piechatzek et al., 2009). Not only that, a systematic review and
meta-analysis on consuming cannabis during adolescence also suggested that cannabis did not lead to
poorer cognitive functions (Scott et al., 2018).
Atypical sampling method used by population-based studies becomes the reason why those
studies often found that consumption of cannabis might not lead to poorer cognitive functions. Studies
with positive findings that cannabis use leads to poor cognitive function usually employ typical
sampling method, i.e., clinical population, which is exposed to bias since most of individuals are
looking for help to overcome cannabis-related problems (Scott et al., 2017). Moreover, if there is
such thing called poorer cognitive functions due to cannabis consumption, it is only temporary and
might be reversed after a period of abstinence (Mizrahi et al., 2017; Scott et al., 2018). Even for chronic
consumer, poorer cognitive functions due to cannabis consumption might be reversed after a period
of abstinence (Mizrahi et al., 2017). Poor cognitive functions due to cannabis consumption ceases in
average of seventy-two hours (Scott et al., 2018).
If poorer cognitive functions proved to be persistent after a period of abstinence, Solowij et al.
5Widodo and Surjaningrum (2014) used central executive, visuo-spatial, phonological loop, and episodic buffer to
assess working memory.
6The title of the research refers to individual with cannabis-related disorder (pecandu) and non-cannabis-related
disorders (bukan pecandu However, the method used in research explain that the groups are divided into
social-recreational consumer and non-consumer (Widodo & Surjaningrum, 2014).
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(2018) suggested a therapy using cannabinoid constituent, i.e., CBD. Two-hundreds milligrams of daily
oral CBD for ten weeks proved to be effective to improve cognitive-related conditions and other-related
symptoms. The improvement occurred without having a period of abstinence, thus did not interrupt
regular pattern of cannabis consumption.
Endocannabinoid System (ECS) and Cannabinoids Effects to Human Brain
Cannabis known for affecting human cognitive and emotion functions (Zanettini et al., 2011). It is due
to the ECS (see annotation number 4) widely spread in various brain regions. Several rationalizations
made to examine ECS, since it plays important roles in regulating learning (Marsicano & Lafenetre,
2009), memory (Bossong, Jager, et al., 2012; Marsicano & Lafenetre, 2009) and emotion processes
(Bossong, Jansma, Hell, Jager, Kahn, et al., 2013).
A meta-analysis on the use of Functional Magnetic Resonance Imaging (fMRI) and/or Positron
Emission Tomography (PET) found that cannabis consumption might increase activation on the
striatum and decrease activation on the anterior cingulate cortex (ACC) and the dorsolateral
prefrontal cortex (DL-PFC). Decreased activation on ACC, DL-PFC and related brain networks
provides neurobiological explanation why cannabis consumption might disrupt task performances.
Furthermore, increase activation on striatal, followed by activation on prefrontal, parietal, and other
limbic areas are associated with reward processing (Yanes et al., 2018).
Animal based research found that ECS plays important roles on rewards processing. Although
it is not yet confirmed on human, ECS correlates with rewards appreciation process. Through fMRI, it
is discovered that inferior parietal and temporal cortex are the most activated regions during rewards
appreciation process on human (G. Hell et al., 2011).
Aside from the endocannabinoids, neurotransmitter often associated with the brain reward
systems is dopamine (Wise & Rompre, 1989). Not only reward systems, dopamine is also an important
neurotransmitter to working memory. Increasing this neurotransmitter or assisting its performance
means improving working memory, vice versa (Gibbs & D’Esposito, 2005; Sawaguchi, 2001). It is
interesting since activating CB1 receptor might improve ECS performance to balance dopaminergic
signaling on various brain regions (Lau & Schloss, 2008).
Other studies suggested that activating ECS might induce poor working memory performance
(Bossong, Jansma, Hell, Jager, Oudman, et al., 2012; Zanettini et al., 2011). It is concluded after
administrating Δ9-THC to 25 healthy participants. Moreover, Δ9-THC also affecting the whole
working memory system, especially the cerebellum, the left dorsolateral prefrontal cortex, the inferior
temporal gyrus, and the inferior parietal gyrus. Poor working memory performance might be due
to Δ9-THC-induced lowered general alertness (Bossong, Jansma, Hell, Jager, Oudman, et al., 2012).
Au contraire, Marsicano and Lafenetre (2009) suggested that high levels of ECS might not induce poor
working memory. In fact, increasing anandamide7 levels and facilitating ECS signaling through fatty
acid amide hydrolase8 (FAAH) inhibitor might improve learning ability9 (Zanettini et al., 2011).
7 Is the first discovered neurotransmitter of ECS. Anandamide means internal bliss (Pinel, 2009).
8 Might induce catabolism to anandamide (Deutsch & Chin, 1993).
9 Is one of the mental functions referred by the word cognition besides motivation, planning, memory, and other
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Working memory is a part of executive functions besides response inhibition10 and cognitive
flexibility11 (Diamond, 2013). Δ9-THC on 500 µg/kg did not induce poor executive functions. It is
concluded using double-blind, placebo controlled, two-way mixed design to 12 occasional and 12
regular cannabis consumers (Ramaekers et al., 2008).
Furthermore, based on systematic review, it could not be determined whether cannabis and/or
Δ
9-THC might induce poor working memory and cognitive flexibility or not. However, Δ9-THC
response inhibition. Neuroimaging results shows that poor respoclearly induces poornse inhibition
is modulated by neural process in the inferior frontal gyrus (Oomen et al., 2018).
Studies that aimed to determine effects of Δ9-THC and CBD to response inhibition found
that Δ9-THC administration might decrease activation on the right inferior frontal and the anterior
cingulate gyrus, whilst CBD to the left temporal and the insula. It is concluded that compared
to CBD, Δ9-THC shows more involvement in response inhibition, since CBD tends to modulate
function that does not correlate with response inhibition. Nevertheless, both Δ9-THC and CBD do
not disrupt response inhibition performance, although Δ9-THC tends to modulate activities within
the brain regions that mediate response inhibition (Borgwardt et al., 2008). Response inhibition
performance tends to be disrupted by Δ9-THC administration on individual with psychosis-like
effects after administration. Neuroimaging results show that there are certain brain regions activation
differences between individual with psychosis-like effects and non-psychosis-like effects. Individual
with psychosis-like effects tend to experience activation in the left parahippocampal gyrus, the left and
right middle temporal gyrus, and the right cerebellum (Atakan et al., 2012). The cerebellum itself is
associated with physical coordination abilities (Smith & Kosslyn, 2014).
Despite no evidence supporting Δ9-THC induce poor response inhibition performances
(Borgwardt et al., 2008), there is evidence of executive function disruption afterΔ9-THC administration
(Bossong, Hell, et al., 2013)—whether the disruption included psychosis-like effects is unknown
(Atakan et al., 2012). During the task performances, the disruption is associated with increasing
activity on a set of brain regions linked to default mode network. Naturally, during task performances
goal-oriented behavior the default mode network would be deactivated. Increasing activity in the
default mode network touted as the main reason for poor executive and cognitive functions (Bossong,
Hell, et al., 2013).
Default mode network is an emerging condition when an individual inactively engaged in task.
While in this condition, the brain planning an action but does not act them out, creating various
scenarios from a single situation. The brain regions are actively involved during this condition is the
medial and lateral frontal cortex. Actively, medial frontal cortex indicates social rumination12 whilst
analysis aspect of thinking abilities (Mai et al., 2005).
10 Including response inhibition (self-control; restraining self from desire and impulsive behavior) and interference
control (selective inhibition to cognition and attention) (Diamond, 2013). Response inhibition correlates with
inhibiting an out-of-context-act or act that would obstruct goal-driven behavior (Mostofsky & Simmonds, 2008).
11 Including creative thinking, using various perspectives, and adapting in a fast and flexible way to a
fast-changing circumstances (Diamond, 2013).
12 During default mode network, we tend to experience rumination concerning our relationships with others and
the position we hold within the social world (Carter et al., 2019).
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lateral frontal cortex indicating sequential thinking patterns suited to handling objects. This condition
would take individual to a solution through free-floating nature of thinking (Carter et al., 2019).
Besides the medial and lateral frontal cortex, there is also the parietal region which enabling
the creation of various scenario (Carter et al., 2019). Activated parietal region during default mode
network enabling individual to recall information from the long-term memory (Sestieri et al., 2011).
Thus, making it more interesting considering ECS plays important role in regulating memory processes
(Bossong, Jager, et al., 2012; Marsicano & Lafenetre, 2009).
Implied regulation might be associate with how inhibiting ECS would increase memory ability
(Zanettini et al., 2011). Furthermore, based on meta-analysis, the ability to learn and remember new
information in chronic cannabis consumer might decrease, although the magnitude of effect is very
small (Grant et al., 2003). Long-term habituation might provide an answer to the decreasing ability
(Riedel & Davies, 2005).
According to various studies, acute (high dose and on relatively short time) cannabis
consumption might induce decreasing ability of learning and memory than regular and chronic
consumption (Riedel & Davies, 2005). However, if there is such thing as decreasing memory ability, it
might be induced by the effects of Δ9-THC to the medial temporal lobe region13 (Bhattacharyya et al.,
2009). Besides, during the coding administration, Δ9-THC tends to reduce the right insular, the right
inferior frontal gyrus, and the left-middle occipital gyrus activity and increasing the bilateral cuneus14
and precuneus15 activity during the information retrieval (Bossong, Jager, et al., 2012).
CB1 antagonists might play roles in improving memory ability by increasing brain plasticity
(Riedel & Davies, 2005). Brain plasticity is a phenomenon that helps brain recovery due to certain
conditions, e.g., stroke and traumatic brain injury (Mateos-Aparicio & Rodriguez-Moreno, 2019). In
addition to improve specific ability such as memory, CB1 antagonists (e.g., CBD) might also improve
cognitive abilities in general through various mechanisms, i.e., pro-inflammatory cytokines, brain
immune cells (e.g., microglia and astrocytes), oxidative stress, inducing neurogenesis, and increasing
serotonin and adenosine (Osborne et al., 2017).
Previous research on cognitive functions deficiency confirmed that CBD could be used to
improve cognitive functions (Osborne et al., 2017). Moreover, based on pre- and clinical studies, ECS
play roles in cognitive deficiency pathophysiology due to psychological disorders (H. Hell et al., 2011).
Ringen et al. (2009) found that consuming cannabis is associated with increasing executive functions
on 133 individuals with bipolar disorder. Increasing executive functions was based on assessment and
comparison of neurocognitive abilities between cannabis and non-cannabis consumers with bipolar
disorder.
Increased executive functions were also found on 11 medical cannabis consumers. All the
11 individuals consumed medical cannabis after 10 years period of abstinence or never have been
consuming before. The 11 individuals consumed cannabis as a medication to anxiety, depressive, sleep
13 Includes hippocampus, perirhinal, ethorhinal, and parahippocampal (Squire et al., 2004).
14 Bilateral cuneus is cuneus and precuneus. Cuneus is located within occipital (Bossong, Jager, et al., 2012).
15 Located between the brain hemispheres. Along with posterior cingulate cortex (PCC), it might play roles in
memory formation, especially when it comes to self (Carter et al., 2019).
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disorder, chronic pain, and other disorders (Gruber et al., 2016)). Furthermore, medical cannabis was
also found to improve activation patterns in the cingulate cortex and the frontal regions—suggesting
normalization of brain function relative to control group. It is observed using fMRI after three months
of medical cannabis consumption. The participants had never consumed cannabis or had through
two years period of abstinence. Besides activation patterns, the participants also showed better
performance on Multi-Source Interference Task (MSIT)16 compared to pre-test (Gruber et al., 2018).
Conclusions
It could not be determined whether cannabis induce positive or negative effects to human
cognitive functions. It is based on various sources we found and used in this article. One of the
factors affecting our conclusions is sampling technique used by each study. Studies that sampled
individuals with cannabis-related disorders tend to find poor cognitive functions. However, research
that sampling on general population (non-clinical or non-correctional facilities) tend not to find poor
cognitive functions.
There are several rationalizations we develop to answer why sampling technique affects the
research results. (1) According to BNN and UI (2017), from 1.7% (3.3 million) of total Indonesian
population aged 10-59 years who consume at least one illicit PS within the last year, there are 14.49%
(489.197 individuals) that could be categorized in having non-injecting substance-use disorder and
1.73% (58,498 individuals) that could be categorized in having injecting substance-use disorder17. The
number is uneven, thus the study using individuals with cannabis-consumption disorders should not
be generalized to the whole population of cannabis consumer.
The next rationalization is (2) related to the health and mental condition of individuals with
cannabis-consumption disorder. The studies sampling on individuals with cannabis-consumption
disorder typically using individuals who were seeking professional help for the condition they have
(Scott et al., 2017). Since they were seeking for professional help, they should have realized that there
are certain conditions within self that not functioning well, have they not? And it is possible that the
conditions itself are linked with their cognitive functions. Besides, we should (3) consider whether it is
a single consumption to cannabis or poly-PS (poly-drugs) consumption (Riedel & Davies, 2005) while
determining the association between consumption and poor cognitive functions.
In addition to the history of PS that ever or being consumed, the consideration must involve
(4) the level of consumption. It is due to the research (Piechatzek et al., 2009; Ross et al., 2020)
that found mild to moderate consumption did not induce significant affect to cognitive functions.
Conversely, chronic and heavy consumption might induce poor cognitive functions. Furthermore, we
should consider the opportunities of the consumers have in sharpening cognitive functions (Widodo
16 Could be used to identify the cognitive networks or attention and to assess integration of the networks (Bush &
Shin, 2006).
17 The exact words used by BNN and UI (2017) are injecting addiction (pecandu suntik) and non-injecting addiction
(pecandu bukan suntik). It is based on route of consumption, using injection and non-injection, and the frequency
of consumption within the last year
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& Surjaningrum, 2014), attention, and goal-based learning (Riedel & Davies, 2005).
Apart from the sampling technique, another factor affecting our conclusions is arose from the
cannabis itself. Opposite nature of cannabinoids constituent, i.e., Δ9-THC and CBD might induce
psychotic-like and antipsychotic effects to its consumer. Psychotic-like effects often associated with
poor cognitive functions, whilst antipsychotic effects alleviated poor cognitive functions. Yet, we
have not considered how both of them works when consumed as cannabis joint which contains
cannabinoids as a whole compound.
Cannabis is also found to affect various brain regions facilitating cognitive functions. It
is discovered after administrating Δ9-THC or CBD and then assessing its effect using fMRI. The
assumptions used to administrate is to activate ECS within the brain. Neuroimaging results of the fMRI
shows that ECS play roles in brain regions correlates with executive functions (Ramaekers et al., 2008),
consist of working memory (Bossong, Jansma, Hell, Jager, Oudman, et al., 2012; Marsicano & Lafenetre,
2009; Zanettini et al., 2011), response inhibition (Atakan et al., 2012; Borgwardt et al., 2008; Bossong,
Hell, et al., 2013; Oomen et al., 2018), and cognitive flexibility (Ramaekers et al., 2008). Moreover, ECS
also play roles in other brain regions associated with memory—memory ability (Bhattacharyya et al.,
2009; Bossong, Jager, et al., 2012; Grant et al., 2003; Marsicano & Lafenetre, 2009; Riedel & Davies, 2005;
Zanettini et al., 2011).
Poor cognitive functions due to consuming cannabis—or certain cannabinoid—might be
induced by increasing activity of the default mode network during task performances—goal-oriented
behavior—the default mode network would be deactivated. Increasing activity in the default mode
network touted as the main reason for poor executive and cognitive functions (Bossong, Hell, et al.,
2013). Moreover, poor cognitive performances after consuming cannabis might be due to ineffective
neural processing, including activated brain regions atypically associated with cognitive performances
(Sagar & Gruber, 2018). However, cannabis or cannabinoid consumption might improve cognitive
functions on individuals with bipolar (Ringen et al., 2009), anxiety, depressive, sleep disorder, chronic
pain (Gruber et al., 2016), and might be other disorders as well (Gruber et al., 2016; G. Hell et al., 2011;
Osborne et al., 2017).
There is evidence suggesting consuming cannabis during adolescence did not induce poor
cognitive functions (Scott et al., 2018). Riedel and Davies (2005) suggested that if there are such thing
as poor cognitive functions due to cannabis consumption, it is more because of lack of attention and
goal-based learning. Furthermore, education might also affect the cognitive functions of cannabis
consumers (Widodo & Surjaningrum, 2014). Widodo and Surjaningrum (2014) argued that the
insignificant difference between control and treatment group on working memory test is due to
the same education background between the groups. The findings shows that although consuming
cannabis, the treatment group still had an opportunity to sharpen their cognitive functions. It also
provides preliminary evidence that by sharpening the cognitive functions, cannabis consumer might
alleviate risk factor of developing poor cognitive functions, especially within the context of Indonesia.
Future research on the cognitive functions of cannabis consumer should really taking population
in which they tried to sample into consideration. It is important especially when it comes to make a
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generalization. The research that sampling on clinical or correctional facility population should not
generalize their results to general population of cannabis consumer that may contain recreational or
abstinence consumer. Moreover, it is delicate to determine causality relationship between consuming
cannabis and poor cognitive functions. Ideally, an experiment of administrating cannabis within
certain amount of time to healthy and identical participants on the term of cognitive functions
would do the trick, yet unethical. Therefore, future research emphasized on correlational relationship
between consuming cannabis within certain population and cognitive functions should take typical
social-demographic factors into consideration.
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